| Factor Information | |
|---|---|
| Data ID | 2484 |
| Factor | Prostaglandin use (n (%)) |
| Description | N/A |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | Treatment |
| Objective | To identify prenatal echocardiographic markers that could predict the need for neonatal intervention in fetuses with right ventricular outflow tract obstruction |
| p Value | 0.0001 |
| Conclusion | Analysis of the pulmonary outflow tract and ductus arteriosus flow in the fetus with complex congenital heart disease can aid in identifying those that will require a neonatal intervention to augment pulmonary blood flow. This has important implications for the planning of delivery strategies. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 604 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | TOF/DORV/PS/UAVC, DORV, PS/UAVC, TOF/UAVC, DORV, TAPVC/DILV, PS/DORV, MS, PS |
| Reference | |
|---|---|
| PMID | 22605656 |
| Year | 2012 |
| Title | Pulmonary outflow tract obstruction in fetuses with complex congenital heart disease: predicting the need for neonatal intervention. |
| Sample | ||
|---|---|---|
| Population | fetus | |
| Source | N/A | |
| Region | Philadelphia, USA | |
| Method | Echocardiograms | |
| Race | North American | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Intervention at >30 days(Treatment) | Intervention at <30 days(Control) |
| Number | 4 (total 26) | 11 (totaL: 13) |
| Age | N/A | N/A |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 4 /26 (15.4%) | 11 /13 (84.6%) |
